Thrombolytic therapy for pulmonary embolism
Zhi‐Liang Zuo, Jirong Yue, Bi Rong Dong, Taixiang Wu, Guan J Liu, Qiukui Hao
Abstract
Thrombolytic therapy is usually reserved for people with clinically serious or massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may dissolve blood clots more rapidly than heparin and may reduce the death rate associated with PE. However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhage. This is the fourth update of the Cochrane review first published in 2006.
Topics & Concepts
MedicinePulmonary embolismOdds ratioPlaceboInternal medicineConfidence intervalAdverse effectClinical trialFibrinolytic agentMeta-analysisRandomized controlled trialIntensive care medicineAntithromboticAlternative medicinePathologyVenous Thromboembolism Diagnosis and ManagementAcute Ischemic Stroke ManagementAcute Myocardial Infarction Research